193 related articles for article (PubMed ID: 22301052)
21. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
[No Abstract] [Full Text] [Related]
22. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
[No Abstract] [Full Text] [Related]
23. Successful topical rapamycin treatment for facial angiofibromata in two children.
Pynn EV; Collins J; Hunasehally PR; Hughes J
Pediatr Dermatol; 2015; 32(3):e120-3. PubMed ID: 25790347
[TBL] [Abstract][Full Text] [Related]
24. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
25. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
Leducq S; Giraudeau B; Tavernier E; Maruani A
J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
[TBL] [Abstract][Full Text] [Related]
26. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
27. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
28. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy.
Park J; Yun SK; Cho YS; Song KH; Kim HU
Dermatology; 2014; 228(1):37-41. PubMed ID: 24401865
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel.
Krakowski AC; Nguyen TA
Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829
[TBL] [Abstract][Full Text] [Related]
30. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
[TBL] [Abstract][Full Text] [Related]
31. Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy.
Negosanti F; Tengattini V; Gurioli C; Neri I
J Cosmet Dermatol; 2018 Oct; 17(5):762-765. PubMed ID: 30123982
[TBL] [Abstract][Full Text] [Related]
32. Segmental tuberous sclerosis in a patient presenting as unilateral facial angiofibromas, periungual fibromas and Shagreen patch.
Sener S; Sasmaz S
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):980-2. PubMed ID: 21845812
[TBL] [Abstract][Full Text] [Related]
33. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
[TBL] [Abstract][Full Text] [Related]
35. Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis.
Cabrera López C; Martí T; Catalá V; Torres F; Mateu S; Ballarín Castán J; Torra Balcells R
Nefrologia; 2011; 31(3):292-8. PubMed ID: 21629335
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
37. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
[TBL] [Abstract][Full Text] [Related]
38. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
39. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
[TBL] [Abstract][Full Text] [Related]
40. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
Krischock L; Beach R; Taylor J
Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
